

Romi Ghose

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12166714/publications.pdf>

Version: 2024-02-01

38
papers

1,075
citations

471509

17
h-index

414414

32
g-index

38
all docs

38
docs citations

38
times ranked

1467
citing authors

#	ARTICLE	IF	CITATIONS
1	Neratinib causes non-recoverable gut injury and reduces intestinal cytochrome P450 3A enzyme in mice. <i>Toxicology Research</i> , 2022, 11, 184-194.	2.1	6
2	Development of a physiologically based pharmacokinetic model to predict irinotecan disposition during inflammation. <i>Chemico-Biological Interactions</i> , 2022, 360, 109946.	4.0	2
3	Irinotecan decreases intestinal UDP-glucuronosyltransferase (UGT) 1A1 via TLR4/MyD88 pathway prior to the onset of diarrhea. <i>Food and Chemical Toxicology</i> , 2022, 166, 113246.	3.6	3
4	Immunization and Drug Metabolizing Enzymes: Focus on Hepatic Cytochrome P450 3A. <i>Expert Review of Vaccines</i> , 2021, 20, 623-634.	4.4	6
5	Effects of inflammation on irinotecan pharmacokinetics and development of a best-fit PK model. <i>Chemico-Biological Interactions</i> , 2020, 316, 108933.	4.0	4
6	Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 1109-1124.	3.3	20
7	Irinotecan-mediated diarrhea is mainly correlated with intestinal exposure to SN-38: Critical role of gut Ugt. <i>Toxicology and Applied Pharmacology</i> , 2020, 398, 115032.	2.8	19
8	Role of oxidative stress in the efficacy and toxicity of herbal supplements. <i>Current Opinion in Toxicology</i> , 2020, 20-21, 36-40.	5.0	7
9	Differential Regulation of Hepatic UDP-glucuronosyltransferase (UGT) 1A1 by Toll-like Receptors during Irinotecan-induced Steatosis. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.5	1
10	Transcriptomic profiling identifies novel mechanisms of transcriptional regulation of the cytochrome P450 (Cyp)3a11 gene. <i>Scientific Reports</i> , 2019, 9, 6663.	3.3	14
11	Neratinib in HER2-Positive Breast Cancer Patients. <i>Annals of Pharmacotherapy</i> , 2019, 53, 612-620.	1.9	22
12	Role of c-Jun-N-Terminal Kinase in Pregnane X Receptor-Mediated Induction of Human Cytochrome P4503A4 In Vitro. <i>Drug Metabolism and Disposition</i> , 2018, 46, 397-404.	3.3	14
13	Impact of diet on irinotecan toxicity in mice. <i>Chemico-Biological Interactions</i> , 2018, 291, 87-94.	4.0	10
14	Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro. <i>Toxicology in Vitro</i> , 2017, 41, 75-82.	2.4	7
15	Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 605-616.	3.3	35
16	Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 901-923.	3.3	84
17	In Vitro Approaches to Study Regulation of Hepatic Cytochrome P450 (CYP) 3A Expression by Paclitaxel and Rifampicin. <i>Methods in Molecular Biology</i> , 2016, 1395, 55-68.	0.9	9
18	Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice. <i>Life Sciences</i> , 2015, 139, 132-138.	4.3	9

#	ARTICLE	IF	CITATIONS
19	Role of Adaptor Protein Toll-Like Interleukin Domain Containing Adaptor Inducing Interferon \hat{A} in Toll-Like Receptor 3- and 4-Mediated Regulation of Hepatic Drug Metabolizing Enzyme and Transporter Genes. <i>Drug Metabolism and Disposition</i> , 2015, 44, 61-67.	3.3	10
20	Role of Constitutive Androstane Receptor in Toll-Like Receptor-Mediated Regulation of Gene Expression of Hepatic Drug-Metabolizing Enzymes and Transporters. <i>Drug Metabolism and Disposition</i> , 2014, 42, 172-181.	3.3	31
21	Chlorpromazine-induced hepatotoxicity during inflammation is mediated by TIRAP-dependent signaling pathway in mice. <i>Toxicology and Applied Pharmacology</i> , 2013, 266, 430-438.	2.8	24
22	Drug Disposition in Pathophysiological Conditions. <i>Current Drug Metabolism</i> , 2012, 13, 1327-1344.	1.2	70
23	Impact of hepatic malignancy on CYP3A4 gene expression. <i>Journal of Surgical Research</i> , 2012, 178, 768-772.	1.6	5
24	Altered Drug Metabolism and Transport in Pathophysiological Conditions. , 2012, , .		2
25	Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. <i>Life Sciences</i> , 2011, 89, 57-64.	4.3	92
26	Differential Role of Toll-Interleukin 1 Receptor Domain-Containing Adaptor Protein in Toll-Like Receptor 2-Mediated Regulation of Gene Expression of Hepatic Cytokines and Drug-Metabolizing Enzymes. <i>Drug Metabolism and Disposition</i> , 2011, 39, 874-881.	3.3	33
27	Role of c-Jun N-terminal kinase (JNK) in regulating tumor necrosis factor-alpha (TNF-.ALPHA.) mediated increase of acetaminophen (APAP) and chlorpromazine (CPZ) toxicity in murine hepatocytes. <i>Journal of Toxicological Sciences</i> , 2010, 35, 163-173.	1.5	38
28	Regulation of gene expression of hepatic drug metabolizing enzymes and transporters by the Toll-like receptor 2 ligand, lipoteichoic acid. <i>Archives of Biochemistry and Biophysics</i> , 2009, 481, 123-130.	3.0	32
29	Regulation of Hepatic Drug-Metabolizing Enzyme Genes by Toll-Like Receptor 4 Signaling Is Independent of Toll-Interleukin 1 Receptor Domain-Containing Adaptor Protein. <i>Drug Metabolism and Disposition</i> , 2008, 36, 95-101.	3.3	32
30	Rosiglitazone attenuates suppression of RXR $\hat{1}\pm$ -dependent gene expression in inflamed liver. <i>Journal of Hepatology</i> , 2007, 46, 115-123.	3.7	34
31	Nuclear Export of Retinoid X Receptor $\hat{I}\pm$ in Response to Interleukin- $1\hat{1}^2$ -mediated Cell Signaling. <i>Journal of Biological Chemistry</i> , 2006, 281, 15434-15440.	3.4	95
32	Restricted Specificity of Xenopus TFIIIA for Transcription of Somatic 5S rRNA Genes. <i>Molecular and Cellular Biology</i> , 2004, 24, 2467-2477.	2.3	8
33	Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: A novel mechanism for reduced hepatic gene expression in inflammation. <i>Nuclear Receptor</i> , 2004, 2, 4.	10.0	127
34	Phosphorylation of Xenopus transcription factor IIIA by an oocyte protein kinase CK2. <i>Biochemical Journal</i> , 2002, 362, 375.	3.7	10
35	Phosphorylation of Xenopus transcription factor IIIA by an oocyte protein kinase CK2. <i>Biochemical Journal</i> , 2002, 362, 375-382.	3.7	9
36	Antiapoptotic Function of Cdk9 (TAK/P-TEFb) in U937 Promonocytic Cells. <i>Journal of Virology</i> , 2001, 75, 1220-1228.	3.4	48

#	ARTICLE	IF	CITATIONS
37	Induction of TAK (Cyclin T1/P-TEFb) in Purified Resting CD4 + T Lymphocytes by Combination of Cytokines. <i>Journal of Virology</i> , 2001, 75, 11336-11343.	3.4	99
38	Inhibition of RNA polymerase III transcription by a ribosome-associated kinase activity. <i>Nucleic Acids Research</i> , 1998, 26, 4758-4764.	14.5	4